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Dystonia is a movement disorder characterized by sustained or intermittent muscle
contractions causing abnormal postures, repetitive movements, or both. Research in
dystonia has been challenged by several factors. First, dystonia is uncommon. Dystonia
is not a single disorder but a family of heterogenous disorders with varied clinical
manifestations and different causes. The different subtypes may be seen by providers
in different clinical specialties including neurology, ophthalmology, otolaryngology, and
others. These issues have made it difficult for any single center to recruit large numbers
of subjects with specific types of dystonia for research studies in a timely manner. The
Dystonia Coalition is a consortium of investigators that was established to address
these challenges. Since 2009, the Dystonia Coalition has encouraged collaboration by
engaging 56 sites across North America, Europe, Asia, and Australia. Its emphasis on
collaboration has facilitated establishment of international consensus for the definition
and classification of all dystonias, diagnostic criteria for specific subtypes of dystonia,
standardized evaluation strategies, development of clinimetrically sound measurement
tools, and large multicenter studies that document the phenotypic heterogeneity and
evolution of specific types of dystonia.
Keywords: dystonia, blepharospasm, cervical dystonia, laryngeal dystonia, rare diseases, spasmodic dysphonia,
torticollis, writer’s cramp
INTRODUCTION TO DYSTONIA
Dystonia is a movement disorder characterized by sustained or intermittent muscle contractions
causing abnormal postures, repetitive movements, or both (1). Dystonic movements are typically
patterned, twisting, or may resemble tremor. Dystonia is often initiated or worsened by voluntary
action and associated with overflowmuscle activation. Dystonia is not a single disorder but a family
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of heterogenous disorders with varied clinical manifestations and
many different causes (2, 3).
The many different clinical manifestations of dystonia are
grouped according to age at onset, body region affected, temporal
aspects, and associated clinical features (1). The term “isolated
dystonia” (previously known as “primary dystonia”) is used
when dystonia is the only movement disorder identified, with
or without tremor. In contrast, the term “combined dystonia”
(previously known as “secondary dystonia” or “dystonia-plus”)
is used when dystonia is combined with other neurological
problems, such as parkinsonism,myoclonus, or ataxia). Themost
common subtypes of isolated dystonia emerge in adults over
a period of weeks or months in one region of the body, with
spread to other regions over many years. Any region of the
body can be affected, but the most common regions include
the neck (cervical dystonia, also known as torticollis), the face
(blepharospasm and related craniofacial dystonias, sometimes
called Meige syndrome), the larynx (laryngeal dystonia, also
known as spasmodic dysphonia), or a limb (e.g., writer’s cramp
or musician’s dystonia). Children are less commonly affected
than adults, although more likely to advance to more severe
generalized forms.
There are many known etiologies for dystonia. They include
lesions of the nervous system, exposure to drugs or medications,
infections and autoimmune processes, and other causes (2–4).
However, for the vast majority of cases of isolated dystonia, a
cause cannot be identified, even after extensive laboratory testing.
Approximately 10–15% of cases have an affected family member.
This observation points to inherited mechanisms. More than 100
genes capable of causing dystonia are known, most of which
cause early-onset or combined forms of dystonia (2, 4, 5). Recent
whole-exome sequencing studies have suggested that an etiology
can be identified in ∼20% of cases, depending on the associated
clinical features (6, 7). A genetic etiology is disclosed more often
in young-onset cases, those where dystonia is combined with
other problems, or those with a family history of dystonia. A
genetic etiology is found in only ∼4% of the most common
adult-onset cases.
Dystonia causes substantial disability (8, 9). For example,
cervical dystonia is associated with neck muscle spasms that
make it difficult for patients to control head movements for
basic activities of daily living such as looking straight ahead
to drive a car, read, see a computer or television screen, or
even walk. Blepharospasm is associated with periocular spasms
leading to frequent sustained eye closures. These spasms make
it difficult to do many of same activities of daily living and
may render subjects functionally blind. Laryngeal dystonia is
associated with spasms of laryngeal muscles making it difficult to
speak and communicate with others. Patients with limb dystonia
may have trouble writing, typing, or walking. When this affects
professionals such as musicians, dystonia can end a career.
Patients with broader distributions of dystonia such as segmental
or generalized patterns have even greater disability.
In addition to the abnormal movements that interfere with
activities of daily living, dystonia is often associated with
pain. Approximately two thirds of all patients with cervical
dystonia have significant pain in the neck or shoulders (10).
Approximately half of all patients with dystonia of the upper limb
have arm or hand pain (11, 12). Many patients with generalized
dystonia have pain relating to themost prominent areas of spasm.
In addition to muscle pain, orthopedic complications that result
from abnormal postures are a source of chronic pain for many
patients with dystonia.
These abnormalities and limitations of mobility and pain
degrade quality of life. In fact, standardized tests for quality of
life in dystonia fall in the same range as patients with Parkinson’s
disease, multiple sclerosis, and stroke (8, 9).
THE NEED FOR NEW TREATMENTS
Existing Treatments
Current treatments include physical therapy to address
spasms or pain. Oral treatments are available to target the
causal mechanisms for a few rare dystonia subtypes (13),
but most are treated symptomatically with benzodiazepines,
anticholinergics, or muscle relaxers (14, 15). The botulinum
toxins are considered first-line treatments for many
patients (16). Surgical interventions are offered for
severe, medically refractory dystonias (17, 18). Deep brain
stimulation (DBS) is most popular, but ablative procedures
involving the basal ganglia or thalamus can also be
helpful (19).
Despite these many treatment options, all have significant
limitations. Physical therapy is popular; but benefits are variable
and often short lived. There are many small open trials describing
their value, but the largest and most rigorous studies fail to show
any consistent benefits (20, 21). The most popular oral agents
produce only partial benefits and doses are limited by side effects
(3, 15).
The botulinum toxins suffer limitations too. Since they must
be injected into affected muscles, they are most useful in
the focal and segmental dystonias where a small number of
muscles can be targeted. Because their benefits last only 2–4
months, injections must be repeated 3–4 times yearly. Despite
dramatic efficacy on standardized tests of motor function in
clinical trials, the botulinum toxins produce low levels of patient
satisfaction, especially toward the end of a treatment cycle (22–
24). Longitudinal studies have indicated that ∼30% of patients
discontinue using botulinum toxins (25), and cross-sectional
studies indicate∼40% of patients are not using botulinum toxins
(14). The reasons for low patient enthusiasm are only partly
understood but appear to include lack of efficacy, side effects,
difficulty in finding experienced injectors, hassle associated with
repeated injections, and cost (24, 25).
For DBS, outcomes depend on etiology (e.g., genetic subtype
or acquired) and certain clinical characteristics (e.g., age,
duration, and combination with other problems) (17, 18, 26, 27).
Therefore, DBS is not a suitable solution for many patients.
Immediate complications are uncommon, but include 1–2%
risk of stroke or infection. In addition, proper programming
requires an experienced team, and it may take many months
to optimize. Long-term complications are not uncommon,
such as lead migration, equipment failure, or infection. In
summary, all existing therapies provide at least partial relief
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of symptoms for many individuals with dystonia, but all have
significant limitations.
Experimental Therapeutics
When considering the development of novel therapeutics,
clinical and etiological heterogeneity among the dystonias creates
challenges. On the one hand, the different clinical manifestations
seem to require different management strategies. In addition,
the varied biological substrates may require targeting different
mechanisms. On the other hand, several observations imply that
certain forms of dystonia are mechanistically related (28, 29). In
fact, there already are some treatments that have broad efficacy
across many clinically and etiologically distinct subtypes, such as
anticholinergics, botulinum toxins, and DBS.
These observations have encouraged attempts to identify the
mechanisms that are shared across multiple types of dystonia.
These mechanisms then become attractive targets for therapeutic
interventions that may be useful across certain subgroups (30–
32). At the genetic level, the identification of a large number of
genes that may cause dystonia has facilitated the identification
of several molecular mechanisms that are shared by at least
certain subgroups of dystonia (5). For example, numerous studies
in both animals and humans have linked dystonia with altered
dopamine transmission. Although there are numerous reports
describing good responses of certain cases to dopamine-related
drugs, they are not generally effective treatments for most types
of dystonia. It has been suggested that the failure of prior
studies to demonstrate more consistent benefits might result
from etiological heterogeneity, and clinical trials in more selected
populations may be needed (33).
Pharmacological studies have also pointed to striatal
cholinergic pathways as a common theme spanning several
different types of dystonia in both animal models (34) and
human studies (35). Although anticholinergic drugs can be at
least partly effective across many different types of dystonia
in humans, they are often poorly tolerated due to side effects
including cognitive impairments, memory loss, dry mouth,
blurred vision, constipation, and urinary retention. Current
clinically available anticholinergics such as trihexyphenidyl non-
specifically block muscarinic receptors. Numerous studies have
focused on identifying novel compounds that may address these
limitations (36). For example, by developing anticholinergics
with more selective effects on the relevant muscarinic receptors
in the striatum, it may be possible to avoid the many side effects
that arise from non-specific blockade of receptors in the cortex
or autonomic system.
Another common theme has involved abnormalities of
neuronal excitability or neural plasticity among individuals with
different types of dystonia (37). Glutamate receptors play a
key role in neuronal excitability. Antagonists targeting several
different subtypes of glutamate receptors (AMPA, NMDA, and
mGluR5) have been shown to reduce dystonic movements
or normalize abnormal striatal physiology in several animal
models of dystonia (38). In humans with cervical dystonia,
an open label study described small improvements with the
non-selective glutamate antagonist riluzole (39), and there are
anecdotal reports describing improvement with amantadine, a
weak NMDA antagonist. These findings have led to interest
into more methodical studies of repurposing glutamate-related
drugs as potential therapeutics for dystonia. For example, the
AMPA antagonist perampanel is FDA approved for epilepsy, and
a trial for subjects with cervical dystonia has recently concluded
recruitment (Clinicaltrials.org, NCT02131467).
Numerous other mechanisms are actively being studied as
therapeutic targets for dystonia. At the end of year 2020,
clinicaltrials.gov listed a total of 291 clinical studies for dystonia.
Of this total, 156 have been completed and 49 are actively
recruiting. Many of these are clinical trials of novel therapeutics
(Table 1). However, many are small or unblinded pilot trials, and
larger more rigorous trials are needed. Clinical trial readiness is
therefore an immediate need. This readiness involves multiple
ingredients including easy identification of research subjects
for efficient recruitment, thorough understanding of phenotypic
heterogeneity and diagnostic criteria for relevant subtypes of
subjects, baseline information on how the disorder evolves
over time, easy identification of experts who can participate
in trials, clinimetrically sound measurement outcome tools for
clinical trials (objective measurement tools and patient-reported
outcomes), and fully objective or biomarker measures.
THE DYSTONIA COALITION (DC)
Mission
The DC was established to address some of the challenges
associated with research in rare disorders by facilitating large-
scale collaborations. Its main focus has been on studies that
address clinical trial readiness. The DC has focused its major
projects on key unmet needs for translating scientific discoveries
into potential new therapies. These unmet needs are identified
via focused workshops, which are conducted in collaboration
with Patient Advocacy Groups (PAGs). The main needs have
included developing a better understanding of the phenotypic
heterogeneity and evolution of various types of dystonia, more
precise and widely accepted diagnostic criteria, appropriate
measurement tools to monitor patients in clinical trials, and
identification of useful biomarkers.
Sponsorship and Endorsement
The DC is sponsored in large part by the National Institute
of Neurological Disorders and Stroke (NINDS) and Office of
Rare Diseases Research (ORDR) in the National Center for
Advancing Translational Sciences (NCATS) at the National
Institute of Health (NIH) through grants NS065701, TR001456,
and NS116025. The DC is part of the NIH Rare Diseases
Clinical Research Network (RDCRN), an initiative of the NIH
to encourage collaborative research for all types of rare disorders
(www.rarediseasesnetwork.org). The DC also receives critical
support and sponsorship from PAGs, industry, professional
societies, and relevant study groups.
PAGs have been integrally involved in all major activities
of the DC. So far, the DC has engaged 17 PAGs across four
countries in its different projects. Many of these regularly
contribute to the DC mission (Table 2). PAGs have been
integrally involved in identifying research topics and designing
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TABLE 1 | Selected clinical trials on dystonias (https://clinicaltrials.gov).
Drug/Intervention Targeted mechanism Type of dystonia Study design Date
Ampicillin Immune system DYT1 dystonia Phase I double-blind 2011–2017







Levetiracetam Synaptic neurotransmission Oromandibular and cranial
dystonia





Cervical dystonia Phase 4 randomized 2014–2017
DBS Pallidal and thalamic nuclei Secondary hemi-dystonia Phase I randomized 2015–Present
Hand physiotherapy Individual finger movement
training
Writer’s cramp Randomized-double blind 2016–Present
Perampanel Glutamate receptor, AMPA Cervical dystonia Phase I/IIa open-label 2017–2020
Zolpidem GABAa receptor chloride
channel modulator/agonist
Writer’s cramp or musician
dystonia
Phase I crossover 2017–Present
Sodium oxybate GABAb receptors Laryngeal dystonia Phase II/III double-blind 2017–Present
Daxibotulinumtoxin A Neuromuscular junction Cervical dystonia Phase III double-blind 2018–2020
Daxibotulinumtoxin A Neuromuscular junction Cervical dystonia Phase III open-label 2018–Present
Botulinum toxin and
treadmill





Deutetrabenazine VMAT2 inhibitor Dystonia Phase I/II open-label 2020–Present
Tele-yoga Mind-body awareness Cervical dystonia Single group intervention 2020–Present
DBS, deep brain stimulation; GABA, gamma-amino butyric acid; VMAT2, vesicular monoamine transporter type 2.
TABLE 2 | Patient advocacy groups currently affiliated with the Dystonia Coalition.
Patient Advocacy Group Country
Benign Essential Blepharospasm Foundation USA
Cure Dystonia Now USA
Dystonia Europe Belgium
Dystonia Ireland Ireland
Dystonia Medical Research Foundation USA
Dystonia Medical Research Foundation, Canada Canada
National Spasmodic Dysphonia Association USA
National Spasmodic Torticollis Association USA
The Dystonia Society USA
Tyler’s Hope USA
DC projects, developing a focus and plan for DC annual
meetings, supporting studies of particular interest, supporting
junior investigators, and facilitating patient recruitment. The
Dystonia Medical Research Foundation (DMRF), in particular,
plays an essential logistical role for the DC infrastructure, at
no additional cost. In addition to aiding the organization of
DC meetings and reviewing projects submitted for DC funding,
DMRF staff provide support for managing subcontracts for
paying all recruiting sites for the various DC projects. This
unique model provides enormous savings for both research costs
and time, enabling DC investigators to focus on clinical and
scientific needs.
Coordination of Sites
The DC has had an open-door policy in which new investigators
and institutions may join the effort at any time. The DC
began in 2009 with eight sites but has since engaged 56 sites
in the North America, Europe, Asia, and Australia (Figure 1,
Supplementary Table 1). Many patients come to these centers
for expert clinical care, as well as research opportunities.
The DC sites are grouped in three tiers. As capabilities and
interests change over time, centers may change tiers. Affiliate
Centers are sites that may not have the ability to recruit
subjects or direct projects but wish to remain informed about
the DC activities and opportunities. Recruiting Centers are
sites with sufficient expertise and clinical volumes to recruit
subjects for clinical research projects. Project Centers are
sites that take responsibility for directing multicenter clinical
research projects. Individual investigators at these sites are given
responsibility for developing and implementing projects using
the DC infrastructure.
All DC activities are centrally coordinated. The coordinating
center supervises the conduct and progress of its main clinical
research projects, its smaller pilot projects, and its career awards.
It also supervises the annual meeting and other activities. For
multicenter projects, data are entered via the internet into
a central database (Figure 2). Training webinars are held for
recruiting sites. These webinars address protocol details such
as recruitment goals, participant eligibility, inclusion/exclusion
criteria, forms/questionnaires, data entry, and reimbursements.
To ensure others outside the DC are aware of its activities,
there are also annual meetings that describe all DC projects,
accomplishments, how to get involved, or how to access data or
materials. The annual meeting is not restricted to members of the
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FIGURE 1 | Dystonia Coalition sites. The main coordinating center is at Emory University (star). Sites responsible for directing large multicenter projects are shown in
blue. Green shows sites that recruit patients for various studies or are recipients of Pilot Project grants or Career Awards. Affiliate sites are shown in black, and closed
sites are shown in red.
DC; it is open to all academic investigators and their staff, PAG
members, and representatives from NIH, and industry.
The central coordinating center also manages the financial
aspects of paying other centers for specific activities. It uses
a direct subcontract to reimburse sites for the effort it takes
to manage large clinical research projects (Figure 3). All other
activities are financially managed through a subcontract with the
DMRF. For example, Recruiting Sites are paid on a fee-for-service
basis for each subject they recruit. The cost per subject depends
on the study they were recruited for, and howmuch effort it takes
the site to collect all data and samples for the study. Pilot projects
and Career awards are also paid through the DMRF.
Sharing Policies
The DC’s open-door policy and broad collaborations have led
to the collection of unprecedented amounts of detailed clinical
data, video recorded examinations, and DNA samples from large
numbers of dystonia subjects from different projects. Data and
materials from DC projects are shared broadly with investigators
both inside and outside the DC (Figure 2). All requests for
data or material are granted, provided that the project has local
IRB approval and does not directly conflict with ongoing DC
studies. Access to DC data and materials is available via three
different processes.
Data or materials may be requested directly from
the DC through the Data and Materials Request Form
(www.dystoniacoalition.org). Access to any original unpublished
data or materials collected and stored by the DC is supervised
by its Executive Committee. Data shared directly by the DC are
provided in a de-identified manner, with a code number only.
Video recordings of the face are classified as Protected Health
Information (PHI) according to Health Insurance Portability
and Accountability Act (HIPAA), and therefore are considered
identifiable data. These recordings are shared only with extra
security provisions. Data and materials collected by the DC
also are compliant with the European General Data Protection
Regulation (EU GDPR). DC policy requires all investigators
requesting data or samples to sign a standard Bylaws agreement,
which explicitly outlines the rights and responsibilities for
sharing, as well as how investigators who contributed the
material are most appropriately acknowledged.
Some of the de-identified key data elements collected by
the DC are also sent to the NINDS Human Genetics Resource
at Coriell, along with a blood sample for DNA extraction
(www.coriell.org). Since the NINDS biorepository is a public
resource, data and materials are collected by Coriell from non-
DC members too. All materials are distributed by the NINDS
Biorepository directly to qualified investigators by direct request.
De-identified data and materials are also stored by the
NCATS-designated Data Management & Coordinating Center
(DMCC). Sharing of these materials is governed by the policies
and procedures of the RDCRN (www.rarediseasesnetwork.org/).
Historically, materials stored by the DMCC have been subject
to an embargo period during the period of active collection,
analysis, and reporting by DC members.
Since 2009, the DC has received 47 requests for data
or materials for studies that were beyond the scope of
its existing projects. Except for projects that competed
Frontiers in Neurology | www.frontiersin.org 5 April 2021 | Volume 12 | Article 660909
Kilic-Berkmen et al. The Dystonia Coalition
FIGURE 2 | Data collection and sharing. Data for large multicenter projects are organized by individual sites (orange) and collected into a central database for
checking, storage, and distribution. All Recruiting Sites (top left) may recruit subjects for the Natural History Project and the Biobank Project. Subgroups of Recruiting
Sites are selected to participate in the other large multicenter projects including the Cervical Dystonia Rating Scale Project, The Blepharospasm Diagnosis and Rating
Scale Project, the Laryngeal Dystonia Diagnosis and Rating Scale Project, and the Patient-Centered Outcomes Project. The Digital Measures Project analyzes video
data collected by all projects. Data submitted to the central database are verified and organized and returned to the sites who manage the large multicenter projects,
and are also shared with multiple additional users. For example, Recruiting Sites may request a summary of data they entered. Data are also shared with the National
Institutes of Health (NIH) and the Data Management and Coordinating Center (DMCC) of the Rare Diseases Clinical Research Network. Subsets of data are also
shared with the National Institute of Neurological Disorders and Stroke (NINDS) Repository at Coriell and with other users by request. DMRF, Dystonia Medial
Research Foundation; JMU, James Madison University, RushU, Rush University; UCSD, University of California in San Diego; UNM, University of New Mexico; WashU;
Washington University in St. Louis.
FIGURE 3 | Financial structure. The majority of funding comes from the NIH Rare Diseases Clinical Research Network (RDCRN), although some funding and other
resources also come from Patient Advocacy Groups. The Administrative Unit at Emory University provides payments by direct subcontracts to sites that organize
large international multicenter projects. The Administrative Unit also has a subcontract with the Dystonia Medical Research Foundation (DMRF), which is responsible
for disbursing funds on a fee-for-service basis to Recruiting Sites (depending on numbers of subjects recruited), smaller projects (such as Pilot Grant Projects or
Career Awards), meetings, consultants, and others. JMU, James Madison University; NIH, National Institutes of Health USA; NINDS, National Institute of Neurological
Disorders and Stroke; RushU, Rush University; UCSD, University of California in San Diego; UNM, University of New Mexico; WashU, Washington University in St.
Louis.
directly with ongoing projects, all requests were granted.
Many of these projects have since been completed and
published, or served as pilot data for grant proposals.
Results from some of these projects are summarized in
Tables 3–5.
Co-authorship Policies
In a large collaborate effort, it is important to appropriately
acknowledge the varied effort of the many different individuals
involved. Guidelines for these acknowledgments are shared
with all DC members in a written document that all
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TABLE 3 | Dystonia Coalition career development award program recipients.
Recipient Institution Year Project title
M. Carbon-Corell, Ph.D. Feinstein Inst, Manhasset, NY, USA 2009 Sensorimotor network activity as a functional imaging
marker for dystonia
M. Zurowski, MD Univ Toronto, Canada 2010 Development of a psychiatric screening tool for cervical
dystonia
A. Espay, MD Univ Cincinnati, Cincinnati, OH, USA 2010 Sensory and emotional processing in psychogenic
dystonia: a functional magnetic resonance imaging study
M. Karimi, MD Washington Univ, St. Louis, MO, USA 2011 Basal ganglia induced plasticity in primary cervical
dystonia
T. Kimberley, PT, Ph.D. Univ Minnesota, Minneapolis, MN, USA 2011 Determining the efficacy of synergistic intervention in
focal hand dystonia with repetitive transcranial magnetic
stimulation and sensorimotor retraining
B. Berman MD Univ Colorado, Denver, CO, USA 2012 Functional connectivity of the basal ganglia in primary
focal dystonia: a pilot study
A. Wagle-Shukla, MD Univ FL, Gainesville, FL, USA 2012 Subthalamic nucleus DBS in primary cervical dystonia: a
pathophysiological insight
M. Bologna, MD Univ Rome, Italy 2013 Effects of cerebellar theta-burst stimulation on arm and
neck movement kinematics in patients with primary
dystonia
S. Pirio-Richardson, MD Univ New Mexico, Albuquerque, NM, USA 2013 Identification of optimal stimulation site for cervical
dystonia symptoms: an exploratory study
D. Peterson, Ph.D. Univ California, San Diego, CA, USA 2013 The contribution of blinks and spasms to blepharospasm
severity
D. Arkadir, MD Hadassah Univ, Israel 2014 Reinforcement learning in DYT1 dystonia
A. Shaikh, MD Case Western, Cleveland, VA, USA 2016 Physiology of head tremor in cervical dystonia
K. Udupa, MD Univ Toronto, Canada 2016 Phase-amplitude coupling of local field potentials in
internal globus pallidus in dystonia
M. Hammer, MD Univ Wisc, Madison, WI, USA 2017 Laryngeal somatosensory evoked cortical potentials in
spasmodic dysphonia-an initial study to elucidate
abnormal sensory mechanisms in laryngeal dystonia
N. Bukhari-Parlakturk, MD, Ph.D. Duke Univ, Durham, NC, USA 2020 Non-invasive neuromodulation to study long-term
plasticity mechanisms in task-specific dystonia
L. Rocchi, MD Univ Rome, Italy 2020 Repetitive somatosensory stimulation in focal hand
dystonia: a study on inhibitory circuitry plasticity of the
somatosensory system and primary motor cortex
investigators sign. In brief, the effort for recruiting patients
and conducting study procedures is acknowledged in part
by including recruiting investigators on relevant publications.
The investigators conducting the study may offer authorship
to any relevant study team members. In addition, other
investigators who recruited patients essential to the study may
also be offered co-authorship. Typical criteria for authorship
for recruiting investigators include at least 20 subjects for
the study under consideration, and evidence for ongoing and
active participation as judged by the recruitment of at least
one subject per month. This policy discourages investigators
from assuming they will be co-authors for recruiting only
a few cases, or from recruiting 20 cases and expecting co-
authorship for all future studies. The study organizers notify
the site PI of any publication taking advantage of cases they
recruited, and the site PI is asked to nominate the most
appropriate co-author at the site. If more than 40 cases were
recruited, the site PI can nominate two co-authors, and an
additional co-author for every additional 20 cases recruited.
Authorship must also meet the usual criteria outlined by Council





Historically, there has been a relatively limited appreciation of the
full phenotypic spectrum and evolution of all types of dystonias.
Most evidence came from relatively small studies, often focusing
on a single subtype of dystonia. Most studies came from single
centers, leading to differences of expert opinion.
A thorough understanding of clinical features and especially
their evolution with time is an essential prerequisite for
testing any disease-modifying therapies that could halt or slow
progression. The aim of Natural History Project has been to
better characterize the heterogeneity of clinical manifestations
in dystonia and how these manifestations evolve over time.
Centers in multiple countries collect a standardized dataset that
they enter into a central database, and record a standardized
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TABLE 4 | Pilot projects funded by the Dystonia Coalition.
Recipient Institution Year Project title Selected outcomes
M. Ledoux, MD Ph.D. Univ Tennessee, Memphis, TN, USA 2009 THAP1 sequence variants in dystonia (40, 41)
G. DeFazio, MD Ph.D. Univ Bari, Italy 2010 Diagnostic guidelines and rating tools for
blepharospasm
(42–44)
E. Roze, MD University Hospitals Pitié Salpêtrière,
Paris, France
2010 Cerebellar cortical plasticity in focal dystonia (45)
K. Bhatia, MD FRCP Univ Coll London, UK 2010 DYT6: A window to mechanisms in primary
dystonia?
(46)
D. Peterson Ph.D. Univ California, San Diego, CA, USA 2010 Increasing CERTainty in blepharospasm (47)
C. Klein, MD Univ Lubeck, Germany 2011 Endophenotypes in focal dystonias In progress
H. Houlden, MRCP, Ph.D. Univ College London, UK 2011 Neuropathology of DYT1 and DYT6 dystonia (46)
S. Frucht, MD Mt. Sinai School of Med, NY, USA 2013 Rating scales for musician’s dystonias (48)
S. Eichenseer, MD Rush Univ, Chicago, IL, USA 2013 A novel method for rating scale assessment
in cervical dystonia
Completed
M. LeDoux, MD Ph.D. Univ Tennessee, Memphis, TN, USA 2013 Targeted sequencing in primary dystonias (49)
H. Jinnah, MD Ph.D. Emory Univ, Atlanta, GA, USA 2013 Resource for induced pluripotent stem cells In progress
S. Norris, MD Washington Univ, St. Louis, MO, USA 2013 Functional magnetic resonance imaging in
laryngeal dystonia and muscle tension
dysphonia
(50)
K. Lohmann, Ph.D. Univ Luebeck, Germany 2013 Whole genome sequencing in focal dystonias In progress
M. Zurowski, MD Univ Toronto, Canada 2014 Development of a psychiatric screening tool
for cervical dystonia
(51–53)
J. Mink, MD Univ Rochester, NY, USA 2015 A rating scale for children with dystonia Completed
M. Hammer, MA, Ph.D. Univ Wisconsin, Whitewater, WI 2020 Non-invasive mechanosensory perturbation
technique to test voice-related motor and
somatosensory cortical responses in
spasmodic dystonia
In progress
video shown in Supplementary Table 2 (69). All data and videos
are checked for accuracy and completeness. Since 2009, more
than 3,200 cases have been recruited, many of whom continue
to be followed. This study has led to several comprehensive
articles that have raised awareness of the phenotypic spectrum of
dystonia (49, 56–58, 62, 63, 70). This study has also led to several
multicenter articles demonstrating progression of adult-onset
dystonias over time (12, 61, 68). These studies provide critical
baseline information for testing any future disease-modifying
treatments, by revealing how many patients would have to be
studied, and for how long (68). This project also led to several
articles summarizing evidence that available treatments are not
as satisfactory as commonly believed (25, 71, 72).
Another outcome from this project relates to the very
definition of dystonia. Prior to starting of DC, the definition
of dystonia varied in different parts of the world. Furthermore,
many subtypes were recognized, but they were organized
in different ways. This heterogeneity led to confusion in
the interpretation of many studies because of diagnostic
uncertainties of the patient cohorts studied. The DC sponsored a
series of meetings with PAGs in America and Europe to develop
an internationally accepted consensus on its definition (1, 73).
The same group also presented a new classification for the many
subtypes. The results of the consensus group were published
in 2013, they were accepted internationally almost immediately,
and the article has been cited more than 1,287 times already.
Now, when articles on dystonia are published, most investigators
understand exactly what subgroups are being studied.
Clinical Rating Tools for Cervical Dystonia
All clinical trials need good outcome measures. The main goal
of this project was to revise and re-evaluate the most popular
clinical rating scale for cervical dystonia, the TWSTRS. This scale
had known deficiencies in its clinimetric properties including
inconsistent scoring among items, double weighting of duration
factors, and variable approach to different aspects of the disorder
(74, 75). Additionally, the scale neglected non-motor features
such as depression and anxiety, which are known to have a strong
impact on quality of life (9, 51, 76–82). This project was designed
to address these shortcomings by producing and clinimetrically
validating the Comprehensive Cervical Dystonia Rating Scale,
which has three modules addressing motor features, non-motor
features, and quality of life. This project completed recruitment
in 2014, with 209 subjects recruited from 10 sites (52, 53).
Thus, a tangible deliverable from this project is a fully validated
and comprehensive rating scale for both motor and non-motor
features of cervical dystonia that can be used in modular format
or in whole.
Although the primary goal of this project has been completed,
the rich database collected inspired a number of secondary
studies (49, 54, 61, 83, 84). Ongoing work involves testing the new
scale by experts in other countries for international validation,
and development of a teaching tape for its use. Most importantly,
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TABLE 5 | Pilot projects supported with Dystonia Coalition data or materials.
Recipient Institution Year of request Topic Status
Neepa Patel, MD; J. Jankovic,
MD
Baylor College of Medicine, Houston,
TX, USA
2012 Sensory tricks in cervical dystonia (54, 55)
M. Zaribaf; G. Kilic-Berkmen,
Ph.D.
Emory Univ, Atlanta, GA, USA 2012, 2019 Family structures in dystonia In progress
A. Shaikh, MD Emory Univ, Atlanta, GA, USA 2013, 2016 Tremor in dystonia (56–60)
T. Douglas, Ph.D.; G.
Kilic-Berkmen, Ph.D.
Emory Univ, Atlanta, GA, USA 2013, 2019 Patterns of segmental and cervical dystonia In progress
H. Sarva, MD; S. Bressman, MD Mt Sinai, New York City, NY, USA 2014 Long term clinical outcomes in DYT1 dystonia In progress
S. Norris, MD Washington Univ, St. Louis, MO, USA 2014, 2016 Clinical characteristics of cervical dystonia (61)
J. Junker, MD Univ Lubeck, Germany 2015 Non-motor features of dystonia (62)
J. Junker, MD; N. Bruggeman,
MD
Univ Lubeck, Germany 2015-2017 Alcohol-responsiveness in Dystonia (63)
J. Junker, MD Univ Lubeck, Germany 2015, 2017 Quality of life in dystonia and its predictors (9)
A. Shaikh, MD Case Western Reserve Univ,
Cleveland, OH, USA
2015 Quantitative analysis of dysphonia and voice
tremor
In progress
S. Pirio-Richardson, MD Univ New Mexico, Albuquerque, NM,
USA
2015, 2017 Patterns of medication use (14, 31)
L. Scorr, MD Emory Univ, Atlanta, GA, USA 2016, 2020 Descriptive study of oromandibular dystonia Manuscript submitted
Y. Sun, Ph.D. Emory Univ, Atlanta, GA, USA 2016 Genome-wide association study for cervical
dystonia
Manuscript in revision
Y. Sun, Ph.D. Emory Univ, Atlanta, GA, USA 2016 Metabolomics in cervical dystonia (64)
N. Patel, MD Henry Ford Health System, Detroit, MI 2016 Substance abuse in dystonia (65)
A. Espay, MD Univ Cincinnati, Cincinnati, OH, USA 2016 Tremor in cervical dystonia (57)
L. Froescheke, Ph.D. Elmhurst College, Elmhurst, IL, USA 2016 Phonatory breaks in spasmodic dysphonia (66)
A. Morris, MD Washington Univ, St. Louis, MO, USA 2016–2018 Acoustic quantification of laryngeal dystonia (67)
B. Berman, MD Univ Colorado, Denver, CO, USA 2016, 2017 Psychiatric symptoms in dystonia Merged with related
project
C. Klein, MD Ph.D. Univ Lubeck, Germany 2017 Penetrance and risk modifying variants in
dystonia
In progress
D. Peterson, Ph.D. UCSD and Salk, LA Jolla, CA, USA 2017 Objective phenotyping in cervical dystonia In progress
H. Sarva, MD Cornell, New York City, NY, USA 2017 Gait in blepharospasm In progress
V. Fung, MD; F. Chang, MD Westmead Hospital, Australia 2017 Torticollis in hemidystonia In progress
S. Cho, MD; M. Hallett, MD NINDS, Bethesda, MD, USA 2017 Sensory tricks in blepharospasm Merged with related
project
B. Berman, MD Univ Colorado, Denver, CO, USA 2017 Patterns of spread in dystonia (68)
S. Norris, MD Washington Univ, St. Louis, MO, USA 2018, 2020 Spread of limb dystonia (12)
D. Martino, MD Univ Calgary, Canada 2018 Demographic and clinical predictors of spread
in adult-onset idiopathic dystonia
In progress
M. Powell, Ph.D. Vanderbilt Univ, Nashville, TN, USA 2019 Artificial intelligence for diagnosing, and
monitoring laryngeal dystonias
In progress
C. Klein, MD Ph.D. Univ Lubeck, Germany 2019 Genome-wide association study for dystonia In progress
N. Harrison, MD; S. Norris, MD Washington Univ, St. Louis, MO, USA 2019 Shoulder dystonia in upper extremity vs.
cervical dystonia
In progress
A. Cotton; H. A. Jinnah, MD
Ph.D.
Emory Univ, Atlanta, GA, USA 2019 Patient-reported outcomes vs. clinical rating
scales
In progress
E. Reid, Ph.D. Loma Linda Univ, Loma Linda, CA 2019 Phonetic analysis of spasmodic dysphonia In progress
K. Lohmann, MD Univ Lubeck, Germany 2020 Large-scale sequencing of dystonia In progress
K. Peall, MD Cardiff Univ, United Kingdom 2020 Predictive models for phenotypic subgroups
across the dystonias
Manuscript submitted
L. Scorr, MD Emory Univ, Atlanta, GA, USA 2020 A descriptive study of blepharospasm In progress
M. Sousa, MD; S. Fox, MD Univ Toronto, Canada 2020 Anxiety in cervical dystonia In progress
M. Tosin, Ph.D. student Rush Univ, Chicago, IL, USA 2020 Head tremor in cervical dystonia In progress
N. Koirala, Ph.D. Haskins Lab, New Haven, CT, USA 2020 Machine learning algorithms for detection of
dystonia
In Progress
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this project has served as a model for other subtypes of dystonia,
where clinical rating scales were less well-developed or absent.
Diagnostic Tools for Laryngeal Dystonia
(Spasmodic Dysphonia)
Workshops aimed at delineating research priorities for laryngeal
dystonia sponsored by the National Spasmodic Dysphonia
Association (NSDA) have repeatedly identified the lack of widely
accepted diagnostic criteria and rating tools as major obstacles for
clinical and basic research for laryngeal dystonias (85, 86). The
goals of this project were parallel to those of the cervical dystonia
project described above. However, in the case of laryngeal
dystonia, widely accepted rating tools were not available. This
project completed recruitment goals in 2015 with 197 subjects
that had a detailed evaluation by a multidisciplinary team
that included a laryngologist, neurologist, and speech language
pathologist. The evaluation included audio and video recordings
of voice characteristics during standard voice tasks, audiovisual
recordings of laryngoscopy to evaluate the vocal folds with
standard tasks, audiovisual recordings of a standard neurological
exam, and a blood sample for the DNA biorepository. Initial
analyses revealed strikingly poor diagnostic agreement, even
among the most experienced experts. As a result, rating tools
could not be developed. Instead, a Delphi panel was established
to develop more universally acceptable diagnostic criteria (70).
Thus, a tangible deliverable of this project is novel diagnostic
criteria that may now be used to distinguish subtypes of laryngeal
dystonia and to discriminate them from related voice disorders.
This project also led to numerous unexpected directions.
For example, several investigators have accessed audiovisual
recordings for different types of perceptual or acoustic analyses,
including machine learning approaches, which are ongoing.
Diagnostic and Rating Tools for
Blepharospasm
Historically, there have been no widely accepted diagnostic
criteria for blepharospasm and related craniofacial dystonias.
Clinical rating tools were available, but suffered numerous
limitations (75). Thus, the goal of this project was to address
these needs. Diagnostic criteria and a novel clinical rating scale
were first established in pilot studies (42, 43), and then tested
in a larger international multicenter design. Eleven centers in
four countries recruited 200 individuals with blepharospasm
along with individuals with other disorders often mistaken for
blepharospasm, such as tics or ptosis. Analyses of these data are
nearly complete, and tangible deliverables from this project will
be internationally validated diagnostic criteria and clinical rating
scale that can support clinical trials.
Patient-Centered Outcomes Project
The projects described above focus mostly on clinician-
determined assessments. Sometimes, clinician assessments do
not match patient views. For example, the botulinum toxins
produce highly significant effects using clinician-rated scales for
many types of dystonia, yet patients often report low levels of
satisfaction (22, 23, 25, 71, 72, 87), with at least 30% discontinuing
use (25). There are many reasons for frequent discontinuation of
botulinum toxins, one of which has been dubbed the yo-yo effect
(31). Typically, injections are required about every 3 months.
Therapeutic benefits emerge within the 1st week and then wear
off after 8–16 weeks, creating a cyclical response known as the
“yo-yo” effect. Although this cyclical effect is widely known, there
are few data describing its frequency, magnitude, and temporal
aspects. In order to design clinical trials for any potential add-on
therapy, it is essential to have clear understanding of the cyclical
responses to botulinum toxins.
The aim of the Patient-Centered Outcomes Project is to
delineate both between-subject and within-subject variations
over time in response to the standard of care treatment with
botulinum toxin, from the perspective of the patient. Existing
tools to measure efficacy rely on clinical rating scales which are
subjective, cumbersome for repeated frequent use, and require
extensive expertise to apply. This project aims instead to develop
a patient-facing tool on a hand-held electronic device, such as
a smartphone. It will focus on the most common dystonias,
cervical dystonia, blepharospasm, and laryngeal dystonia. This
tool will have 10–15 disorder-specific questions that can be
answered on a more frequent basis than existing scales (e.g.,
weekly), to provide a more direct and more precise temporal
appreciation of responses over time. This tool will be ideal for
any novel clinical trial that proposes an “add-on” therapy, as
well as for comparing durations of responses among different
botulinum toxins.
Objective Measures Project
Current tools for diagnosis and assessment of severity
depend almost entirely on subjective clinician-rated or
patient-rated tools, but advances in modern technology
have opened the door to more objective strategies. The
Objective Measures Project aims to exploit technological
advances in digital tools to measure the severity of dystonia.
Specifically, this project will exploit advances in computer
vision and machine learning to semi-automatically analyze
common abnormalities evident in video recordings of
blepharospasm, cervical dystonia, and laryngeal dystonia.
This new technology could ultimately replace subjective clinical
rating scales as outcome measures and enable remote assessment
for telemedicine.
In pilot studies, this strategy was used to quantify blinks
and spasms among subjects with blepharospasm (47). The
results demonstrated good correlations with clinical rating
scales. Additional studies will address other manifestations of
blepharospasm, such as apraxia of eyelid opening. They will
also exploit similar technology for assessment of abnormal
head movements in cervical dystonia and abnormal vocal fold
movements in laryngeal dystonia. Thus, an important deliverable
from this project is a truly objective measure of abnormal
movements in dystonia, which may be applied to videos for
remote assessments.
Biobank Project
Biomarkers can also provide valuable tools for clinical
trials. Genes can provide useful diagnostic tools. However,
existing genes account for only a small fraction of all
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subjects with dystonia and do not predict penetrance,
severity, onset, or rate of progression. There are no
practical biomarkers for addressing severity of the
dystonias. Neuroimaging abnormalities provide a potential
“endo-phenotype” (88, 89), but most are not practical as
clinical biomarkers. Several studies also have identified
subclinical defects in sensory function (90–92), but their
significance and whether they can serve as biomarkers
remains unclear.
The aim of the Biobank Project is to develop a resource
that permits sharing of DNA samples with carefully annotated
clinical data. This resource was started with DNA collection
in 2009 and currently has more than 3,000 samples. This
is the largest and most carefully clinically annotated
biobank in the world. DNA samples have been accessed
numerous times, for example, for validation studies (49).
They have also been accessed for genome-wide association
studies (GWAS) and whole exome sequencing (WES)
studies, which are ongoing. In 2020, the Biobank added
collection of RNA and plasma that will allow for additional
studies including transcriptomics, proteomics or lipidomics,
epigenomics, and others. A pilot study of metabolomics has
provided hints that this approach may be successful (64).
The goal is to create a resource for biomarker discovery
and validation.
OTHER DYSTONIA COALITION ACTIVITIES
In addition to the large multicenter studies described above,
the DC also encourages the development of new investigators
and new studies relevant to dystonia. Like the large multicenter
projects, these other activities focus on clinical or translational
research. A collaborative approach is encouraged. Scientific
advisory board members from dystonia PAGs are integrally
involved in the review of potential new projects, results of the
review process are shared with PAG leaders, and PAGs are
involved in final project selection and often funding too.
Career Development Award
The goal of the Career Development Award is to promote career
development for investigators interested in research in dystonia
and related rare disorders. The DC is particularly interested
in applications aiming to exploit data and/or resources already
collected by the DC or projects that encourage collaborations by
involving different centers of the DC. All applicants may apply
regardless whether they are part of the DC or not. US citizenship
and affiliation with a US institution are not required.Most awards
are directed toward junior faculty interested in developing
careers in clinical and translational research in dystonia, butmore
senior investigators may apply if they are redirecting their efforts
from another area of research to dystonia. Advanced postdoctoral
fellows who are transitioning to their first faculty appointment
may also be considered. Applications are reviewed by the DC,
and successful applicants are asked to provide written progress
reports. Since 2009, the DC received a total of 40 applications for
this award and provided funding for 16 candidates in 4 different
countries. A summary of recipients and their projects is provided
in Table 3. Further information regarding this opportunity can
be found at www.dystoniacoalition.org.
Pilot Projects Program
The goal of the Pilot Projects Program is to foster promising
pilot studies to a point where they can be published or
compete for independent funding. The DC is particularly
interested in applications focusing on clinical or translational
projects with direct relevance to dystonia, projects aiming to
exploit data and/or resources already collected by the DC,
and/or projects that encourage collaborations by involving
different centers of the DC. Applicants may come from DC
centers, although membership in the DC is not required.
US citizenship and affiliation with a US institution are not
required. Applications are reviewed by the DC, and successful
applicants are asked to provide written progress reports. Since
2009, the DC received 80 applications and provided funding
for 16 applications in five different countries (Table 4). Most
projects have received $10,000–50,000 in financial support.
Further information regarding this opportunity can be found
at www.dystoniacoalition.org.
The DC also supports Pilot Projects by providing DC data
and materials, rather than direct financial support. For example,
the DC has received more than 47 formal requests for data
or materials. All requests were approved except for two, which
were requests that overlapped with existing projects (Table 5).
Further information regarding how to make a request for
data or materials is described above in Sharing Policies, and
at www.dystoniacoalition.org.
SUMMARY AND FUTURE DIRECTIONS
The dystonias are a rare and very heterogeneous group of
disorders. They have a profound impact on quality of life,
and existing treatments all have significant limitations. New
or improved treatments are sorely needed. There are multiple
ongoing efforts to improve existing therapies or develop entirely
novel approaches. Any novel approach to therapy will require
rigorous clinical trials. As a result, the majority of studies by the
DC have focused on clinical trial readiness. TheDChas addressed
the need to identify experts who can participate in trials. It
has also conducted multiple studies of clinical heterogeneity
among different dystonias, the progressive nature of some
dystonias, diagnostic criteria, clinical rating tools, patient-
reported outcomes, digital measurement tools, and biomarkers
for diagnosis or severity. Along the way, the DC has supported
more than 150 articles, numerous grant proposals, and 13
meetings or workshops.
The dystonia community looks forward to a day when all
affected individuals can get a rapid and expert diagnosis, and
ready access to effective treatments that control the debilitating
consequences of the disorder. The dystonia community also
looks forward to reaching a better understanding of the etiology
and pathogenesis of dystonia, so that truly disease-modifying
therapies can be designed to halt progress or even reverse it.
For a rare disorder like dystonia, The Dystonia Coalition has
demonstrated that broad collaborations and cooperation are
essential to these goals.
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